Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.53 |
| ▸ | SORD | Q00796 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371074 | 0.86 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10HPGDSORD | |
| SCHEMBL24126288 | 0.82 | ACHE (0.57) | KDM4EALDH1A1HSD17B10HPGDACHE | |
| SCHEMBL13806018 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10HPGDSORD | |
| SCHEMBL18234750 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1HSD17B10HPGDSORD | |
| SCHEMBL7904079 | 0.82 | SORD (0.55) | KDM4EALDH1A1HSD17B10HPGDACHE | |
| SCHEMBL18228454 | 0.82 | SORD (0.55) | KDM4EALDH1A1HSD17B10HPGDACHE | |
| SCHEMBL13806030 | 0.82 | SORD (0.55) | KDM4EALDH1A1HSD17B10HPGDSORD | |
| SCHEMBL24827231 | 0.81 | ACHE (0.52) | ALDH1A1ACHEKMT2A | |
| SCHEMBL19861584 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10HPGDSORD | |
| SCHEMBL27810118 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10HPGDSORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021018023-A1 | SMALL MOLECULE GLP-1 RECEPTOR MODULATOR | 济南泰达领创医药技术有限公司 | 2021-02-04 | — | — | WO | disclosed |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-05-15 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | KDM4E 2865/4885ALDH1A1 2127/4885HSD17B10 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.